# Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

> **NCT06361589** · — · RECRUITING · sponsor: **Sichuan Cancer Hospital and Research Institute** · enrollment: 200 (estimated)

## Conditions studied

- ALK-positive Non-small Cell Lung Cancer
- Real World Study

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT06361589
- **Lead sponsor:** Sichuan Cancer Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2026-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06361589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06361589, "Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06361589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*